Arbor Biotechnologies
History
| Year | Detail |
|---|---|
| 2016 | Arbor was founded by Feng Zhang, David Walt, David Scott, and Winston Yan in Massachusetts, U.S. |
| 2017 | The company has raised $15.6M in Series A funding. |
| 2018 | Discovered Cas13d, a compact RNA-targeting CRISPR nuclease, executed Vertex research collaboration and license agreement and discovered additional subtypes of type V CRISPR-Cas systems. |
| 2019 | Optimized first therapeutic candidate for mammalian activity and Discovered type V CRISPR-associated transposase system. |
| 2020 | Multiple nuclease candidates demonstrate mammalian activity and Engineering efforts yield candidates with Cas9 equivalent activity. |
| 2021 | Expanded partnership with Vertex to include ex vivo engineered cell therapies, Closed $215 Million oversubscribed Series B Financing, and Entered into gene-editing technology licensing deal with Lonza. |
| 2022 | Entered license agreement with Edigene to advance ex vivo engineered cell therapy programs, Established a Engineered Cas12i2 as platform for genome editing. |
| 2023 | Expanded strategic partnership with Vertex to include RT editing and Established partnership with Ginkgo Bioworks to accelerate RT editor screening/optimization. |